NEJM â Collection Updates for Statistics

SPECIAL ARTICLE: Outcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label Use

Thu, 12Â NovÂ 2009 00:00:00 -05:00

Background: There is good evidence of selective outcome reporting in published reports of randomized trials.

Methods: We examined reporting practices for trials of gabapentin funded by Pfizer and Warner-Lambert's subsidiary, Parke-Davis...

EDITORIAL: The Confirmatory Trial in Comparative-Effectiveness Research

Alan M. Garber, M.D., Ph.D., and Mark A. Hlatky, M.D. — Thu, 08Â OctÂ 2009 00:00:00 -05:00

Despite the infusion of more than $1 billion through the American Recovery and Reinvestment Act of 2009 and the potential commitment of much more money, there will never be enough...

STATISTICS IN MEDICINE: The Delayed-Start Study Design

Ralph B. D'Agostino, Sr., Ph.D. — Thu, 24Â SepÂ 2009 00:00:00 -05:00

To advance our understanding of treatments for diseases that progress slowly but that are ultimately debilitating, such as Alzheimer's disease, Parkinson's disease, rheumatoid arthritis, and chronic obstructive pulmonary disease, it...

SPECIAL REPORT: Premature Release of Data from Clinical Trials of Ezetimibe

Robert M. Califf, M.D., Robert A. Harrington, M.D., and Michael A. Blazing, M.D. — Thu, 13Â AugÂ 2009 00:00:00 -05:00

The recent controversy about whether the cholesterol-lowering drug ezetimibe causes cancer raises urgent questions about the systems we use to develop drugs and medical devices and then to evaluate their...

CORRESPONDENCE: Calculation of Number Needed to Treat

Samy Suissa, Ph.D. — Thu, 23Â JulÂ 2009 00:00:00 -05:00

To the Editor: The number of patients who would need to be treated to prevent a given adverse outcome in one patient, called the number needed to treat, is often...

BOOK REVIEW:

Thu, 19Â MarÂ 2009 00:00:00 -05:00

Progress in the United States is traditionally measured in terms of economic growth, trade, and investment, and that makes The Measure of America a welcome book. Its editors introduce the...

ORIGINAL ARTICLE: Long-Term Ozone Exposure and Mortality

Thu, 12Â MarÂ 2009 00:00:00 -05:00

Background: Although many studies have linked elevations in tropospheric ozone to adverse health outcomes, the effect of long-term exposure to ozone on air pollutionârelated mortality remains uncertain. We examined the...

BOOK REVIEW:

Thu, 29Â JanÂ 2009 00:00:00 -05:00

How health risks are investigated, perceived, and discussed is hardly objective and dispassionate. Rather, a variety of cultural, political, personal, and other factors influence which potential hazards are studied, how...

ORIGINAL ARTICLE: General and Abdominal Adiposity and Risk of Death in Europe

Thu, 13Â NovÂ 2008 00:00:00 -05:00

Background: Previous studies have relied predominantly on the body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) to assess the association of adiposity...

BOOK REVIEW:

Thu, 30Â OctÂ 2008 00:00:00 -05:00

Molecular epidemiology extends traditional epidemiology studies based on questionnaires by incorporating genetic and molecular measures as biomarkers of exposure, risk, and prognosis. The explosion of genetic information and laboratory methods...

EDITORIAL: Identifying and Addressing Safety Signals in Clinical Trials

Thomas R. Fleming, Ph.D. — Thu, 25Â SepÂ 2008 00:00:00 -05:00

Interventions for the prevention or treatment of disease that are based on our understanding of the pathobiologic features of the illness can provide benefit in how a patient feels or...

EDITORIAL: Ezetimibe and Cancer â An Uncertain Association

Thu, 25Â SepÂ 2008 00:00:00 -05:00

The randomized clinical trial is considered to be the most reliable tool to assess the efficacy and safety of new drugs. At times, however, randomized trials detect adverse events that...

SPECIAL ARTICLE: Analyses of Cancer Data from Three Ezetimibe Trials

Thu, 25Â SepÂ 2008 00:00:00 -05:00

Background: Five years of statin therapy lowers low-density lipoprotein (LDL) cholesterol substantially and, over a 5-year period, results in reductions in the incidence of cardiovascular events. The Simvastatin and Ezetimibe...

BOOK REVIEW:

Thu, 18Â SepÂ 2008 00:00:00 -05:00

Obesity is ultimately the result of an imbalance between energy intake and energy expenditure, but this simplistic equation belies the fact that obesity is also a multifactorial disease with complex...

PERSPECTIVE: Redefining Quality â Implications of Recent Clinical Trials

Thu, 12Â JunÂ 2008 00:00:00 -05:00

Simple approaches to patient care are better â except when they are not. Recent clinical studies are leading to a reexamination of the paradigm whereby efforts to prevent vascular disease...

EDITORIAL: Stranded in the Periphery â The Increasing Marginalization of Smokers

Steven Schroeder, M.D. — Thu, 22Â MayÂ 2008 00:00:00 -05:00

One of the greatest health advances in the past three decades has been the continuing decline in the prevalence of smoking, which recently hit a modern age-adjusted low of 19%...

SPECIAL ARTICLE: The Collective Dynamics of Smoking in a Large Social Network

Nicholas A. Christakis, M.D., Ph.D., M.P.H., and James H. Fowler, Ph.D. — Thu, 22Â MayÂ 2008 00:00:00 -05:00

Background: The prevalence of smoking has decreased substantially in the United States over the past 30 years. We examined the extent of the person-to-person spread of smoking behavior and the...

EDITORIAL: ACE Inhibitors in Cardiovascular Disease â Unbeatable?

John J.V. McMurray, M.D. — Thu, 10Â AprÂ 2008 00:00:00 -05:00

The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET, NCT00153101), reported by Yusuf et al.1 in this issue of the Journal, has important lessons for clinical...

SPECIAL ARTICLE: Violence-Related Mortality in Iraq from 2002 to 2006

Iraq Family Health Survey Study Group — Thu, 31Â JanÂ 2008 00:00:00 -05:00

Background: Estimates of the death toll in Iraq from the time of the U.S.-led invasion in March 2003 until June 2006 have ranged from 47,668 (from the Iraq Body Count)...

PERSPECTIVE: Estimating Excess Mortality in Post-Invasion Iraq

Thu, 31Â JanÂ 2008 00:00:00 -05:00

There is no set formula for accurately tallying deaths from humanitarian crises. When a population becomes destabilized, estimation of mortality is likely to be severely challenged. In the case of...

EDITORIAL: Drug-Eluting Stents â Pushing the Envelope beyond the Labels?

Joseph P. Carrozza, Jr., M.D. — Thu, 24Â JanÂ 2008 00:00:00 -05:00

Unlike jurors, clinicians frequently must make decisions without the luxury of the totality of evidence. When we speak of evidence-based medicine, it is important to remember that available data may...

SPECIAL ARTICLE: Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

Thu, 17Â JanÂ 2008 00:00:00 -05:00

Background: Evidence-based medicine is valuable to the extent that the evidence base is complete and unbiased. Selective publication of clinical trials â and the outcomes within those trials â can...

SPECIAL REPORT: Statistics in Medicine â Reporting of Subgroup Analyses in Clinical Trials

Thu, 22Â NovÂ 2007 00:00:00 -05:00

Medical research relies on clinical trials to assess therapeutic benefits. Because of the effort and cost involved in these studies, investigators frequently use analyses of subgroups of study participants to...

EDITORIAL: Scanning the Genome for Coronary Risk

Anthony Rosenzweig, M.D. — Thu, 02Â AugÂ 2007 00:00:00 -05:00

Coronary artery disease remains an enormous clinical problem, affecting more than 15 million people in the United States alone, where it is the most common cause of death (accounting for...

EDITORIAL: Publishing Genomewide Association Studies

Jeffrey M. Drazen, M.D., and Elizabeth G. Phimister, Ph.D. — Thu, 02Â AugÂ 2007 00:00:00 -05:00

On July 18, 2007, two original research articles appeared on the Journal's Web site (and will be published in this and later print issues) conveying the results of âgenomewide association...

PERSPECTIVE: Drinking from the Fire Hose â Statistical Issues in Genomewide Association Studies

Thu, 02Â AugÂ 2007 00:00:00 -05:00

The past 3 months have seen the publication of a series of studies examining the inherited genetic underpinnings of common diseases such as prostate cancer, breast cancer, diabetes, and in...

EDITORIAL: Network Medicine â From Obesity to the âDiseasomeâ

Albert-LÃ¡szlÃ³ BarabÃ¡si, Ph.D. — Thu, 26Â JulÂ 2007 00:00:00 -05:00

A recent study reported that among people who carried a single copy of the high-risk allele for the FTO gene, which is associated with fat mass and obesity, the risk...

SPECIAL ARTICLE: The Spread of Obesity in a Large Social Network over 32 Years

Nicholas A. Christakis, M.D., Ph.D., M.P.H., and James H. Fowler, Ph.D. — Thu, 26Â JulÂ 2007 00:00:00 -05:00

Background: The prevalence of obesity has increased substantially over the past 30 years. We performed a quantitative analysis of the nature and extent of the person-to-person spread of obesity as...

EDITORIAL: Anti-TNF Antibodies for Crohn's Disease â In Pursuit of the Perfect Clinical Trial

James D. Lewis, M.D., M.S.C.E. — Thu, 19Â JulÂ 2007 00:00:00 -05:00

For decades, many patients with Crohn's disease required prolonged courses of corticosteroids, repeated surgeries, or both, despite treatment with 5-aminosalicylic acid (mesalamine) or immunomodulators such as azathioprine. The introduction of...

PERSPECTIVE: Is Zero the Ideal Death Rate?

Thu, 12Â JulÂ 2007 00:00:00 -05:00

Massachusetts recently joined New York, New Jersey, and Pennsylvania in reporting death rates associated with cardiac surgery for individual surgeons â another wave in the tide of public reporting that...

EDITORIAL: The Record on Rosiglitazone and the Risk of Myocardial Infarction

Bruce M. Psaty, M.D., Ph.D., and Curt D. Furberg, M.D., Ph.D. — Thu, 05Â JulÂ 2007 00:00:00 -05:00

In this issue of the Journal,1 Home and colleagues report interim results from the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes, or RECORD, study (NCT00379769). The...

EDITORIAL: Rosiglitazone and Cardiotoxicity â Weighing the Evidence

David M. Nathan, M.D. — Thu, 05Â JulÂ 2007 00:00:00 -05:00

The recently published meta-analysis by Nissen and Wolski,1 which suggested a significant increase in the risk of myocardial infarction associated with treatment with rosiglitazone (Avandia) and an increase of similar...

EDITORIAL: Rosiglitazone â Continued Uncertainty about Safety

Jeffrey M. Drazen, M.D., Stephen Morrissey, Ph.D., and Gregory D. Curfman, M.D. — Thu, 05Â JulÂ 2007 00:00:00 -05:00

On May 21, 2007, the Journal published a meta-analysis by Nissen and Wolski1 that indicated an increased cardiovascular risk associated with rosiglitazone (Avandia), a thiazolidinedione used to treat type 2...

HEALTH LAW, ETHICS, AND HUMAN RIGHTS: Compact versus Contract â Industry Sponsors' Obligations to Their Research Subjects

Michelle M. Mello, J.D., Ph.D., M.Phil., and Steven Joffe, M.D., M.P.H. — Thu, 28Â JunÂ 2007 00:00:00 -05:00

Public unease about industry's influence over clinical research has never been greater. Recent events have elevated concerns about financial ties among investigators, academic medical centers, and industry sponsors,1234 and disquieting...

EDITORIAL: Clinical Trial Registration â Looking Back and Moving Ahead

Christine Laine, M.D., M.P.H. — Thu, 28Â JunÂ 2007 00:00:00 -05:00

In 2005, the International Committee of Medical Journal Editors (ICMJE) initiated a policy requiring investigators to deposit information about trial design into an accepted clinical trials registry before the onset...

SPECIAL ARTICLE: Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980â2000

Thu, 07Â JunÂ 2007 00:00:00 -05:00

Background: Mortality from coronary heart disease in the United States has decreased substantially in recent decades. We conducted a study to determine how much of this decrease could be explained...

PERSPECTIVE: Challenges in Using Observational Studies to Evaluate Adverse Effects of Treatment

Thu, 26Â AprÂ 2007 00:00:00 -05:00

In this issue of the Journal, Friis-MÃ¸ller and colleagues (pages 1723â1735) report on results from a prospective observational study involving more than 23,000 patients infected with HIV. The study, called...

SPECIAL REPORT: The Decrease in Breast-Cancer Incidence in 2003 in the United States

Thu, 19Â AprÂ 2007 00:00:00 -05:00

An initial analysis of data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registries shows that the age-adjusted incidence rate of breast cancer in women in the...

EDITORIAL: Clinical Trials in the Elderly â A Concept Comes of Age

Lillian L. Siu, M.D. — Thu, 12Â AprÂ 2007 00:00:00 -05:00

A well-conducted, randomized, controlled trial provides a high level of evidence to guide clinical management. Although this tenet is accepted in all fields of medicine, including oncology, considerable challenges are...

PERSPECTIVE: Cesarean Delivery and the RiskâBenefit Calculus

Thu, 01Â MarÂ 2007 00:00:00 -05:00

In 1937, an article in the Journal describing 10 years of births at Boston City Hospital revealed an overall rate of cesarean delivery of about 3%.1 Recently released 2005 data...

PERSPECTIVE: NSAID Trials and the Choice of Comparators â Questions of Public Health Importance

Thu, 25Â JanÂ 2007 00:00:00 -05:00

Under ideal conditions, large clinical trials would be designed so that they satisfied the marketing needs of the pharmaceutical manufacturers that generally sponsor them and, at the same time, answered...

SPECIAL ARTICLE: Release from Prison â A High Risk of Death for Former Inmates

Thu, 11Â JanÂ 2007 00:00:00 -05:00

Background: The U.S. population of former prison inmates is large and growing. The period immediately after release may be challenging for former inmates and may involve substantial health risks. We...

ORIGINAL ARTICLE: Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death

Thu, 21Â DecÂ 2006 00:00:00 -05:00

Background: Few investigations have evaluated the incremental usefulness of multiple biomarkers from distinct biologic pathways for predicting the risk of cardiovascular events.

Methods: We measured 10 biomarkers in 3209 participants attending...

PERSPECTIVE: The Limitations of Risk Factors as Prognostic Tools

Thu, 21Â DecÂ 2006 00:00:00 -05:00

Identification of new risk factors for specific diseases is an enduring theme in medical research. Advances in molecular biology, genetics, and computational biology are accelerating the pace of this work....

PERSPECTIVE: Observational Studies of Drug Safety â Aprotinin and the Absence of Transparency

Thu, 23Â NovÂ 2006 00:00:00 -05:00

The full safety profile of a new drug is rarely known at the time of approval by the Food and Drug Administration (FDA). Most drug-development programs designed for treatments of...

PERSPECTIVE: Surviving Sepsis â Practice Guidelines, Marketing Campaigns, and Eli Lilly

Thu, 19Â OctÂ 2006 00:00:00 -05:00

Practice guidelines approved by expert panels are intended to standardize care in such a way as to improve health outcomes. In recent years, the developers of such standards have started...

EDITORIAL: Alzheimer's Disease â Clinical Trials and the Logic of Clinical Purpose

Jason Karlawish, M.D. — Thu, 12Â OctÂ 2006 00:00:00 -05:00

Agitation, aggression, delusions, and hallucinations are among the most common and disabling symptoms of Alzheimer's disease. These problems diminish the quality of life for both the patient and caregiver.1 They...

PERSPECTIVE: Time-to-Event Analyses for Long-Term Treatments â The APPROVe Trial

Thu, 13Â JulÂ 2006 00:00:00 -05:00

The Adenomatous Polyp Prevention on Vioxx (APPROVe) trial1 compared rofecoxib with placebo in the prevention of recurrent colorectal polyps, but the researchers also collected data on adverse cardiovascular events, including...

PERSPECTIVE: The Challenge of Subgroup Analyses â Reporting without Distorting

Thu, 20Â AprÂ 2006 00:00:00 -05:00

Subgroup analyses are an important part of the analysis of a comparative clinical trial. However, they are commonly overinterpreted1234 and can lead to further research that is misguided or, worse,...

PERSPECTIVE: First, Gather the Data

Thu, 26Â JanÂ 2006 00:00:00 -05:00

It is a cornerstone of medical practice to âfirst, do no harm.â Yet the body of evidence that is sufficient to demonstrate efficacy for a new drug is rarely large...

PERSPECTIVE: Evidence-Based Use of Cardiac Procedures and Devices

Mark A. Hlatky, M.D. — Thu, 20Â MayÂ 2004 00:00:00 -05:00

The fundamental principle of evidence-based medicine is that clinical practice should rest on a sound scientific foundation established by clinical studies involving human subjects. The level of evidence needed for...

SOUNDING BOARD: Data Safety and Monitoring Boards

Arthur S. Slutsky, M.D., and James V. Lavery, Ph.D. — Thu, 11Â MarÂ 2004 00:00:00 -05:00

Data safety and monitoring boards, also known by other names (e.g., data monitoring committees), were first introduced in the 1960s as a mechanism for monitoring interim data in clinical trials...

EDITORIAL: Adjuvant Chemotherapy for Lung Cancer â A New Standard of Care

Ronald H. Blum, M.D. — Thu, 22Â JanÂ 2004 00:00:00 -05:00

In patients with cancer who undergo surgery with curative intent but who are known to be at risk for a recurrence, postoperative chemotherapy increases the chance of a cure. The...

EDITORIAL: Choosing between Clinical Prediction Rules

Donald M. Yealy, M.D., and Thomas E. Auble, Ph.D. — Thu, 25Â DecÂ 2003 00:00:00 -05:00

Clinicians currently order imaging studies for most patients with blunt head or neck trauma if there is even a remote possibility of cervical-spine injury, in order to avoid missing a...

EDITORIAL: Letrozole after Tamoxifen for Breast Cancer â What Is the Price of Success?

John Bryant, Ph.D., and Norman Wolmark, M.D. — Thu, 06Â NovÂ 2003 00:00:00 -05:00

In this issue of the Journal, Goss et al.1 report results from a trial that will have a considerable effect on the treatment of early-stage breast cancer. The study was...

PERSPECTIVE: Population-Based Studies of Adverse Drug Effects

Wayne A. Ray, Ph.D. — Thu, 23Â OctÂ 2003 00:00:00 -05:00

The prescription of medications has long been the most frequent therapeutic intervention in medicine. In 2000 in the United States, 173 million people filled 2.2 billion outpatient prescriptions, accounting for...

PERSPECTIVE: Novel Risk Markers and Clinical Practice

Teri Manolio, M.D., Ph.D. — Thu, 23Â OctÂ 2003 00:00:00 -05:00

A growing understanding of the importance of the rupture of atherosclerotic plaque in the pathogenesis of coronary events has led to the identification of an expanding array of markers of...

EDITORIAL: Clinical Trials and Rare Diseases

Stephen W. Lagakos, Ph.D. — Thu, 12Â JunÂ 2003 00:00:00 -05:00

In this issue of the Journal, Gallin and colleagues1 report the results of a clinical trial of itraconazole for the prevention of severe fungal infection in children and adults with...

EDITORIAL: Interpreting Incomplete Data in Studies of Diet and Weight Loss

James H. Ware, Ph.D. — Thu, 22Â MayÂ 2003 00:00:00 -05:00

The prevalence of obesity among Americans 20 to 74 years of age increased from 15 percent during the period between 1976 and 1980 to 27 percent in 19991 and continues...

PERSPECTIVE: The National Emphysema Treatment Trial â How Strong Is the Evidence?

James H. Ware, Ph.D. — Thu, 22Â MayÂ 2003 00:00:00 -05:00

The National Emphysema Treatment Trial (NETT), reported in this issue of the Journal (pages 2059â2073) raises interesting questions about the interpretation of secondary analyses of data collected in clinical trials....

EDITORIAL: The Powerful Placebo and the Wizard of Oz

Thu, 24Â MayÂ 2001 00:00:00 -05:00

Some myths really ought to be true. We react with surprise and pleasure when we encounter them and then believe them when they neatly and comfortably help to explain some...

SPECIAL ARTICLE: Is the Placebo Powerless? â An Analysis of Clinical Trials Comparing Placebo with No Treatment

AsbjÃ¸rn HrÃ³bjartsson, M.D., and Peter C. GÃ¸tzsche, M.D. — Thu, 24Â MayÂ 2001 00:00:00 -05:00

Background: Placebo treatments have been reported to help patients with many diseases, but the quality of the evidence supporting this finding has not been rigorously evaluated.

Methods: We conducted a systematic...

EDITORIAL: Designing and Funding Clinical Trials of Novel Therapies

Thu, 08Â MarÂ 2001 00:00:00 -05:00

New therapies require rigorous evaluation before they become part of routine clinical care. The process of evaluating new drugs and devices is well established. When a new approach to treatment...

SPECIAL ARTICLE: A Comparison of Observational Studies and Randomized, Controlled Trials

Kjell Benson, B.A., and Arthur J. Hartz, M.D., Ph.D. — Thu, 22Â JunÂ 2000 00:00:00 -05:00

Background: For many years it has been claimed that observational studies find stronger treatment effects than randomized, controlled trials. We compared the results of observational studies with those of randomized,...

EDITORIAL: Passive Smoking, Coronary Heart Disease, and Meta-Analysis

Thu, 25Â MarÂ 1999 00:00:00 -05:00

Meta-analysis â the formal combination of the research results from multiple studies â is widely used, but with little general understanding of its limitations and uncertainties. There is something quite...

EDITORIAL: Equivalence Trials

Thu, 16Â OctÂ 1997 00:00:00 -05:00

In the typical two-group clinical trial with outcomes of either success or failure, investigators are interested in finding out whether an innovative treatment, T, reduces the frequency of failure relative...

EDITORIAL: The Promise and Problems of Meta-Analysis

Thu, 21Â AugÂ 1997 00:00:00 -05:00

Meta-analysis has acquired a substantial following among both statisticians and clinicians. The technique was developed as a way to summarize the results of different research studies of related problems. Meta-analysis...

SPECIAL ARTICLE: Discrepancies between Meta-Analyses and Subsequent Large Randomized, Controlled Trials

Thu, 21Â AugÂ 1997 00:00:00 -05:00

Background: Meta-analyses are now widely used to provide evidence to support clinical strategies. However, large randomized, controlled trials are considered the gold standard in evaluating the efficacy of clinical interventions.

Methods:...

NEJM â Collection Updates for Statistics

SPECIAL ARTICLE: Outcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label Use

EDITORIAL: The Confirmatory Trial in Comparative-Effectiveness Research

STATISTICS IN MEDICINE: The Delayed-Start Study Design

SPECIAL REPORT: Premature Release of Data from Clinical Trials of Ezetimibe

CORRESPONDENCE: Calculation of Number Needed to Treat

BOOK REVIEW:

ORIGINAL ARTICLE: Long-Term Ozone Exposure and Mortality

BOOK REVIEW:

ORIGINAL ARTICLE: General and Abdominal Adiposity and Risk of Death in Europe

BOOK REVIEW:

EDITORIAL: Identifying and Addressing Safety Signals in Clinical Trials

EDITORIAL: Ezetimibe and Cancer â An Uncertain Association

SPECIAL ARTICLE: Analyses of Cancer Data from Three Ezetimibe Trials

BOOK REVIEW:

PERSPECTIVE: Redefining Quality â Implications of Recent Clinical Trials

EDITORIAL: Stranded in the Periphery â The Increasing Marginalization of Smokers

SPECIAL ARTICLE: The Collective Dynamics of Smoking in a Large Social Network

EDITORIAL: ACE Inhibitors in Cardiovascular Disease â Unbeatable?

SPECIAL ARTICLE: Violence-Related Mortality in Iraq from 2002 to 2006

PERSPECTIVE: Estimating Excess Mortality in Post-Invasion Iraq

EDITORIAL: Drug-Eluting Stents â Pushing the Envelope beyond the Labels?

SPECIAL ARTICLE: Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

SPECIAL REPORT: Statistics in Medicine â Reporting of Subgroup Analyses in Clinical Trials

EDITORIAL: Scanning the Genome for Coronary Risk

EDITORIAL: Publishing Genomewide Association Studies

PERSPECTIVE: Drinking from the Fire Hose â Statistical Issues in Genomewide Association Studies

EDITORIAL: Network Medicine â From Obesity to the âDiseasomeâ

SPECIAL ARTICLE: The Spread of Obesity in a Large Social Network over 32 Years

EDITORIAL: Anti-TNF Antibodies for Crohn's Disease â In Pursuit of the Perfect Clinical Trial

PERSPECTIVE: Is Zero the Ideal Death Rate?

EDITORIAL: The Record on Rosiglitazone and the Risk of Myocardial Infarction

EDITORIAL: Rosiglitazone and Cardiotoxicity â Weighing the Evidence

EDITORIAL: Rosiglitazone â Continued Uncertainty about Safety

HEALTH LAW, ETHICS, AND HUMAN RIGHTS: Compact versus Contract â Industry Sponsors' Obligations to Their Research Subjects

EDITORIAL: Clinical Trial Registration â Looking Back and Moving Ahead

SPECIAL ARTICLE: Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980â2000

PERSPECTIVE: Challenges in Using Observational Studies to Evaluate Adverse Effects of Treatment

SPECIAL REPORT: The Decrease in Breast-Cancer Incidence in 2003 in the United States

EDITORIAL: Clinical Trials in the Elderly â A Concept Comes of Age

PERSPECTIVE: Cesarean Delivery and the RiskâBenefit Calculus

PERSPECTIVE: NSAID Trials and the Choice of Comparators â Questions of Public Health Importance

SPECIAL ARTICLE: Release from Prison â A High Risk of Death for Former Inmates

ORIGINAL ARTICLE: Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death

PERSPECTIVE: The Limitations of Risk Factors as Prognostic Tools

PERSPECTIVE: Observational Studies of Drug Safety â Aprotinin and the Absence of Transparency

PERSPECTIVE: Surviving Sepsis â Practice Guidelines, Marketing Campaigns, and Eli Lilly

EDITORIAL: Alzheimer's Disease â Clinical Trials and the Logic of Clinical Purpose

PERSPECTIVE: Time-to-Event Analyses for Long-Term Treatments â The APPROVe Trial

PERSPECTIVE: The Challenge of Subgroup Analyses â Reporting without Distorting

PERSPECTIVE: First, Gather the Data

PERSPECTIVE: Evidence-Based Use of Cardiac Procedures and Devices

SOUNDING BOARD: Data Safety and Monitoring Boards

EDITORIAL: Adjuvant Chemotherapy for Lung Cancer â A New Standard of Care

EDITORIAL: Choosing between Clinical Prediction Rules

EDITORIAL: Letrozole after Tamoxifen for Breast Cancer â What Is the Price of Success?

PERSPECTIVE: Population-Based Studies of Adverse Drug Effects

PERSPECTIVE: Novel Risk Markers and Clinical Practice

EDITORIAL: Clinical Trials and Rare Diseases

EDITORIAL: Interpreting Incomplete Data in Studies of Diet and Weight Loss

PERSPECTIVE: The National Emphysema Treatment Trial â How Strong Is the Evidence?

EDITORIAL: The Powerful Placebo and the Wizard of Oz

SPECIAL ARTICLE: Is the Placebo Powerless? â An Analysis of Clinical Trials Comparing Placebo with No Treatment

EDITORIAL: Designing and Funding Clinical Trials of Novel Therapies

SPECIAL ARTICLE: A Comparison of Observational Studies and Randomized, Controlled Trials

EDITORIAL: Passive Smoking, Coronary Heart Disease, and Meta-Analysis

EDITORIAL: Equivalence Trials

EDITORIAL: The Promise and Problems of Meta-Analysis

SPECIAL ARTICLE: Discrepancies between Meta-Analyses and Subsequent Large Randomized, Controlled Trials

NEJM â Collection Updates for Statistics

EDITORIAL: Ezetimibe and Cancer â An Uncertain Association

PERSPECTIVE: Redefining Quality â Implications of Recent Clinical Trials

EDITORIAL: Stranded in the Periphery â The Increasing Marginalization of Smokers

EDITORIAL: ACE Inhibitors in Cardiovascular Disease â Unbeatable?

EDITORIAL: Drug-Eluting Stents â Pushing the Envelope beyond the Labels?

SPECIAL REPORT: Statistics in Medicine â Reporting of Subgroup Analyses in Clinical Trials

PERSPECTIVE: Drinking from the Fire Hose â Statistical Issues in Genomewide Association Studies

EDITORIAL: Network Medicine â From Obesity to the âDiseasomeâ

EDITORIAL: Anti-TNF Antibodies for Crohn's Disease â In Pursuit of the Perfect Clinical Trial

EDITORIAL: Rosiglitazone and Cardiotoxicity â Weighing the Evidence

EDITORIAL: Rosiglitazone â Continued Uncertainty about Safety

HEALTH LAW, ETHICS, AND HUMAN RIGHTS: Compact versus Contract â Industry Sponsors' Obligations to Their Research Subjects

EDITORIAL: Clinical Trial Registration â Looking Back and Moving Ahead

SPECIAL ARTICLE: Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980â2000

EDITORIAL: Clinical Trials in the Elderly â A Concept Comes of Age

PERSPECTIVE: Cesarean Delivery and the RiskâBenefit Calculus

PERSPECTIVE: NSAID Trials and the Choice of Comparators â Questions of Public Health Importance

SPECIAL ARTICLE: Release from Prison â A High Risk of Death for Former Inmates

PERSPECTIVE: Observational Studies of Drug Safety â Aprotinin and the Absence of Transparency

PERSPECTIVE: Surviving Sepsis â Practice Guidelines, Marketing Campaigns, and Eli Lilly

EDITORIAL: Alzheimer's Disease â Clinical Trials and the Logic of Clinical Purpose

PERSPECTIVE: Time-to-Event Analyses for Long-Term Treatments â The APPROVe Trial

PERSPECTIVE: The Challenge of Subgroup Analyses â Reporting without Distorting

EDITORIAL: Adjuvant Chemotherapy for Lung Cancer â A New Standard of Care

EDITORIAL: Letrozole after Tamoxifen for Breast Cancer â What Is the Price of Success?

PERSPECTIVE: The National Emphysema Treatment Trial â How Strong Is the Evidence?

SPECIAL ARTICLE: Is the Placebo Powerless? â An Analysis of Clinical Trials Comparing Placebo with No Treatment